Stay updated with breaking news from Pelican Expression Technology. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Merck & Co Inc (NYSE: MRK) released results from the STRIDE-3 Phase 3 trial evaluating V116, the company's investigational 21-valent
Ligand retains all Pelican commercial royalties and will own 49.9% of Primrose Bio, Inc. as a stand-alone private company with leading technologies in synthetic biologyLigand contributes $15 million in exchange for economic interest in select Primrose programsLigand improves cash expense outlook and raises EPS guida...
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) entered into a merger agreement under which its subsidiary, Pelican Technology Holdings Inc, has become a wholly owned subsidiary of Primrose Bio Inc.
By Ben Glickman Ligand Pharmaceuticals said it was spinning off its subsidiary Pelican Technology Holdings and merging Pelican with Primordial Genetics. The...
/PRNewswire/ -- Primrose Bio, Inc., a stand-alone private biotechnology company focused on developing state-of-the-art discovery and production systems for...